E
2.58
-0.19 (-6.82%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Eledon Pharmaceuticals, Inc. | 混合的 | 看跌 |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | -1.1 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 2.0 |
| 相对估值 | NA |
| 财务健康 | 0.0 |
| 宏观环境 | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| 平均 | -0.35 |
|
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 1.40% |
| 机构持股比例 | 68.39% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Defilade Capital Management, L.P. | 30 Jun 2026 | 3,525,338 |
| Ensign Peak Advisors, Inc | 30 Jun 2026 | 2,101,224 |
| Sphera Funds Management Ltd. | 30 Jun 2026 | 1,191,187 |
该时间范围内无数据。
该时间范围内无数据。
投资组合